Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
XACDURO - sulbactam/durlobactam injection
Product / population
Adults at least 18 years old; HABP/VABP caused by susceptible Acinetobacter baumannii-calcoaceticus complex.
Renal method
CrCl by Cockcroft-Gault, mL/min.
Source revision
Prescribing information revised May 2023; DailyMed page updated November 26, 2025.
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Exact-130 threshold differs between printed sources
At CrCl exactly 130 mL/min, the printed UCSF band uses a six-hour interval; the official label places 130 in the four-hour band.
What to reconcile: Do not average these intervals. Confirm current labeling and the local protocol before clinical use.
Source difference identified; final patient-specific adjudication required.
DailyMed / NLM; manufacturer prescribing information · Adults at least 18 years old; HABP/VABP caused by susceptible Acinetobacter baumannii-calcoaceticus complex.
Renal method: CrCl by Cockcroft-Gault, mL/min. Source date: Prescribing information revised May 2023; DailyMed page updated November 26, 2025. Retrieved: 2026-09-07
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Each dose contains sulbactam 1 g plus durlobactam 1 g. Infuse every dose intravenously over 3 hours.
CrCl
Dose interval
At least 130
Every 4 hours
45-129
Every 6 hours
30-44
Every 8 hours
15-29
Every 12 hours
Below 15, new treatment
Every 12 hours for the first three doses at 0, 12 and 24 hours; then every 24 hours
Below 15, decline during treatment
Every 24 hours
For intermittent HD, initiate dosing immediately after HD; administer doses after the session. Monitor fluctuating renal function and revise the interval accordingly. This extract does not provide a CRRT regimen.
RDM33-official-sulbactam-durlobactam-C1 · Source locator: Sections 1.1, 2.1-2.3 and Table 1.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.